• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Andrew X. Zhu, MD, PhD


  • Hato T, Goyal L, Greten TF, Duda DG, Zhu AX.Immune checkpoint blockade in hepatocellular carcinoma: Current progress and future directions.Hepatology. 2014 Jun 9.
  • Zhu AX, Borger DR, Kim Y, Cosgrove D, Ejaz A, Alexandrescu S, Groeschl RT, Deshpande V, Lindberg JM, Ferrone C, Sempoux C, Yau T, Poon R, Popescu I, Bauer TW, Gamblin TC, Gigot JF, Anders RA, Pawlik TM.Genomic Profiling of Intrahepatic Cholangiocarcinoma: Refining Prognosis and Identifying Therapeutic Targets.Ann Surg Oncol. 2014 Jun 3.
  • Wo JY, Childs SK, Szymonifka J, Mamon HJ, Ryan DP, Blaszkowsky LS, Kwak EL, Ferrone CR, Allen JN, Zhu AX, Wolpin BM, Chan JA, Abrams TA, McCleary NJ, Fernandez-Del Castillo C, Hong TS.Delaying chemoradiation until after completion of adjuvant chemotherapy for pancreatic cancer may not impact local control.Practical Radiation Oncology.;4(2):e117-23.
  • Hong TS, Ryan DP, Borger DR, Blaszkowsky LS, Yeap BY, Ancukiewicz M, Deshpande V, Shinagare S, Wo JY, Boucher Y, Wadlow RC, Kwak EL, Allen JN, Clark JW, Zhu AX, Ferrone CR, Mamon HJ, Adams J, Winrich B, Grillo T, Jain RK, DeLaney TF, Fernandez-Del Castillo C, Duda DG.A Phase 1/2 and Biomarker Study of Preoperative Short Course Chemoradiation With Proton Beam Therapy and Capecitabine Followed By Early Surgery for Resectable Pancreatic Ductal Adenocarcinoma.Int J Radiat Oncol Biol Phys. 2014 May 24.
  • Yoon SS, Aloia TA, Haynes AB, Kambadakone A, Kaur H, Vauthey JN, Ferrone CR, Zhu AX, Wo JY, Crane C, Hong TS.Surgical placement of biologic mesh spacers to displace bowel away from unresectable liver tumors followed by delivery of dose-intense radiation therapy.Practical Radiation Oncology.;4(3):167-73.
  • Hayano K, Lee SH, Yoshida H, Zhu AX, Sahani DV.Fractal Analysis of CT Perfusion Images for Evaluation of Antiangiogenic Treatment and Survival in Hepatocellular Carcinoma.Acad Radiol. 2014 May;21(5):654-60.
  • Borger DR, Goyal L, Yau T, Poon RT, Ancukiewicz M, Deshpande V, Christiani DC, Liebman HM, Yang H, Kim H, Yen K, Faris JE, Iafrate AJ, Kwak EL, Clark JW, Allen JN, Blaszkowsky LS, Murphy JE, Saha SK, Hong TS, Wo JY, Ferrone CR, Tanabe KK, Bardeesy N, Straley KS, Agresta S, Schenkein DP, Ellisen LW, Ryan DP, Zhu AX.Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma.Clin Cancer Res. 2014 Apr 1;20(7):1884-90.
  • Kalva SP, Pectasides M, Liu R, Rachamreddy N, Surakanti S, Yeddula K, Ganguli S, Wicky S, Blaszkowsky LS, Zhu AX.Safety and effectiveness of chemoembolization with drug-eluting beads for advanced-stage hepatocellular carcinoma.Cardiovasc Intervent Radiol. 2014 Apr;37(2):381-7.
  • Hyder O, Marques H, Pulitano C, Marsh JW, Alexandrescu S, Bauer TW, Gamblin TC, Sotiropoulos GC, Paul A, Barroso E, Clary BM, Aldrighetti L, Ferrone CR, Zhu AX, Popescu I, Gigot JF, Mentha G, Feng S, Pawlik TM.A Nomogram to Predict Long-term Survival After Resection for Intrahepatic Cholangiocarcinoma: An Eastern and Western Experience.JAMA Surg. 2014 Mar 5.
  • Russo AL, Ryan DP, Borger DR, Wo JY, Szymonifka J, Liang WY, Kwak EL, Blaszkowsky LS, Clark JW, Allen JN, Zhu AX, Berger DL, Cusack JC, Mamon HJ, Haigis KM, Hong TS.Mutational and clinical predictors of pathologic complete response in the treatment of locally advanced rectal cancer.J Gastrointest Cancer. 2014 Mar;45(1):34-9.
  • Wo JY, Dawson LA, Zhu AX, Hong TS.An emerging role for radiation therapy in the treatment of hepatocellular carcinoma and intrahepatic cholangiocarcinoma.Surg Oncol Clin N Am. 2014 Apr;23(2):353-68.
  • Hayano K, Yoshida H, Zhu AX, Sahani DV.Fractal Analysis of Contrast-Enhanced CT Images to Predict Survival of Patients with Hepatocellular Carcinoma Treated with Sunitinib.Dig Dis Sci. 2014 Feb 22.
  • Russo AL, Borger DR, Szymonifka J, Ryan DP, Wo JY, Blaszkowsky LS, Kwak EL, Allen JN, Wadlow RC, Zhu AX, Murphy JE, Faris JE, Dias-Santagata D, Haigis KM, Ellisen LW, Iafrate AJ, Hong TS.Mutational analysis and clinical correlation of metastatic colorectal cancer.Cancer. 2014 Feb 5.
  • Goyal L, Supko JG, Berlin J, Blaszkowsky LS, Carpenter A, Heuman DM, Hilderbrand SL, Stuart KE, Cotler S, Senzer NN, Chan E, Berg CL, Clark JW, Hezel AF, Ryan DP, Zhu AX.Phase 1 study of N(1),N(11)‑diethylnorspermine (DENSPM) in patients with advanced hepatocellular carcinoma.Cancer Chemother Pharmacol. 2013 Dec;72(6):1305-14.
  • Chen Y, Huang Y, Reiberger T, Duyverman AM, Huang P, Samuel R, Hiddingh L, Roberge S, Koppel C, Lauwers GY, Zhu AX, Jain RK, Duda DG.Differential effects of sorafenib on liver versus tumor fibrosis mediated by SDF1α/CXCR4 axis and Gr-1+ myeloid cell infiltration in mice.Hepatology. 2013 Nov 14.
  • Zhu AX, Finn RS, Mulcahy M, Gurtler J, Sun W, Schwartz JD, Dalal RP, Joshi A, Hozak RR, Xu Y, Ancukiewicz M, Jain RK, Nugent FW, Duda DG, Stuart K.A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer.Clin Cancer Res. 2013 Nov 11.
  • Hyder O, Marsh JW, Salem R, Petre EN, Kalva S, Liapi E, Cosgrove D, Neal D, Kamel I, Zhu AX, Sofocleous CT, Geschwind JF, Pawlik TM.Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis.Ann Surg Oncol. 2013 Nov;20(12):3779-86.
  • Chan JA, Blaszkowsky L, Stuart K, Zhu AX, Allen J, Wadlow R, Ryan DP, Meyerhardt J, Gonzalez M, Regan E, Zheng H, Kulke MH.A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor.Cancer. 2013 Sep 1;119(17):3212-8.
  • Sahani DV, Jiang T, Hayano K, Duda DG, Catalano OA, Ancukiewicz M, Jain RK, Zhu AX.Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy.J Hematol Oncol. 2013;6:51.
  • Faris JE, Blaszkowsky LS, McDermott S, Guimaraes AR, Szymonifka J, Huynh MA, Ferrone CR, Wargo JA, Allen JN, Dias LE, Kwak EL, Lillemoe KD, Thayer SP, Murphy JE, Zhu AX, Sahani DV, Wo JY, Clark JW, Fernandez-Del Castillo C, Ryan DP, Hong TS.FOLFIRINOX in Locally Advanced Pancreatic Cancer: The Massachusetts General Hospital Cancer Center Experience.Oncologist. 2013 May 8.
  • Michaelson MD, Zhu AX, Ryan DP, McDermott DF, Shapiro GI, Tye L, Chen I, Stephenson P, Patyna S, Ruiz-Garcia A, Schwarzberg AB.Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study.Br J Cancer. 2013 Apr 16;108(7):1393-401.
  • Wolpin BM, Ng K, Zhu AX, Abrams T, Enzinger PC, McCleary NJ, Schrag D, Kwak EL, Allen JN, Bhargava P, Chan JA, Goessling W, Blaszkowsky LS, Supko JG, Elliot M, Sato K, Regan E, Meyerhardt JA, Fuchs CS.Multicenter Phase II Study of Tivozanib (AV-951) and Everolimus (RAD001) for Patients With Refractory, Metastatic Colorectal Cancer.Oncologist. 2013 Apr 11.
  • Zhu AX, Ancukiewicz M, Supko JG, Sahani DV, Blaszkowsky LS, Meyerhardt JA, Abrams TA, McCleary NJ, Bhargava P, Muzikansky A, Sheehan S, Regan E, Vasudev E, Knowles M, Fuchs CS, Ryan DP, Jain RK, Duda DG.Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study.Clin Cancer Res. 2013 Mar 15;19(6):1557-66.
  • Hyder O, Hatzaras I, Sotiropoulos GC, Paul A, Alexandrescu S, Marques H, Pulitano C, Barroso E, Clary BM, Aldrighetti L, Ferrone CR, Zhu AX, Bauer TW, Walters DM, Groeschl R, Gamblin TC, Marsh JW, Nguyen KT, Turley R, Popescu I, Hubert C, Meyer S, Choti MA, Gigot JF, Mentha G, Pawlik TM.Recurrence after operative management of intrahepatic cholangiocarcinoma.Surgery. 2013 Mar 15.
  • Zhu AX, Gold PJ, El-Khoueiry AB, Abrams TA, Morikawa H, Ohishi N, Ohtomo T, Philip PA.First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma.Clin Cancer Res. 2013 Feb 15;19(4):920-8.
  • Goyal L, Muzumdar MD, Zhu AX.Targeting the HGF/c-MET Pathway in Hepatocellular Carcinoma.Clin Cancer Res. 2013 Feb 6.
  • Kalva SP, Pectasides M, Yeddula K, Ganguli S, Blaszkowsky LS, Zhu AX.Factors affecting survival following chemoembolization with doxorubicin-eluting microspheres for inoperable hepatocellular carcinoma.J Vasc Interv Radiol. 2013 Feb;24(2):257-65.
  • Zhu AX, Salem R.Combining transarterial chemoembolization with radiofrequency ablation for hepatocellular carcinoma: one step forward?.J Clin Oncol. 2013 Feb 1;31(4):406-8.
  • Zhu AX.New agents on the horizon in hepatocellular carcinoma.Ther Adv Med Oncol. 2013 Jan;5(1):41-50.
  • Zhu AX, Knox JJ.Adjuvant therapy for intrahepatic cholangiocarcinoma: the debate continues.Oncologist. 2012;17(12):1504-7.
  • Jiang T, Zhu AX, Sahani DV.Established and novel imaging biomarkers for assessing response to therapy in hepatocellular carcinoma.J Hepatol. 2012 Aug 31.
  • Chan JA, Ryan DP, Zhu AX, Abrams TA, Wolpin BM, Malinowski P, Regan EM, Fuchs CS, Kulke MH.Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumors.Endocr. Relat. Cancer. 2012 Oct;19(5):615-23.
  • Zhu AX.Sorafenib use in hepatocellular carcinoma in Japan: early experience and impact on clinical practice.Clin Drug Investig. 2012 Aug 8;32 Suppl 2:1-2.
  • Meyerhardt JA, Ancukiewicz M, Abrams TA, Schrag D, Enzinger PC, Chan JA, Kulke MH, Wolpin BM, Goldstein M, Blaszkowsky L, Zhu AX, Elliott M, Regan E, Jain RK, Duda DG.Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer.PLoS ONE. 2012;7(6):e38231.
  • Kalva SP, Iqbal SI, Yeddula K, Blaszkowsky LS, Akbar A, Wicky S, Zhu AX.Transarterial chemoembolization with Doxorubicin-eluting microspheres for inoperable hepatocellular carcinoma.Gastrointest Cancer Res. 2011 Jan;4(1):2-8.
  • Kozyreva ON, Chi D, Clark JW, Wang H, Theall KP, Ryan DP, Zhu AX.A multicenter retrospective study on clinical characteristics, treatment patterns, and outcome in elderly patients with hepatocellular carcinoma.Oncologist. 2011;16(3):310-8.
  • Zhu AX, Duda DG, Sahani DV, Jain RK.HCC and angiogenesis: possible targets and future directions.Nat Rev Clin Oncol. 2011 Mar 8.
  • Deshpande V, Nduaguba A, Zimmerman SM, Kehoe SM, Macconaill LE, Lauwers GY, Ferrone C, Bardeesy N, Zhu AX, Hezel AF.Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma.BMC Cancer. 2011;11:60.
  • Zhu AX, Hezel AF.Development of molecularly targeted therapies in biliary tract cancers: reassessing the challenges and opportunities.Hepatology. 2011 Feb;53(2):695-704. Review.
  • Chan JA, Blaszkowsky LS, Enzinger PC, Ryan DP, Abrams TA, Zhu AX, Temel JS, Schrag D, Bhargava P, Meyerhardt JA, Wolpin BM, Fidias P, Zheng H, Florio S, Regan E, Fuchs CS.A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma.Ann Oncol. 2011 Jan 7.
  • Kulke MH, Chan JA, Meyerhardt JA, Zhu AX, Abrams TA, Blaszkowsky LS, Regan E, Sidor C, Fuchs CS.A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors.Cancer Chemother Pharmacol. 2010 Oct 20.
  • Zhu AX, Duda DG, Ancukiewicz M, di Tomaso E, Clark JW, Miksad R, Fuchs CS, Ryan DP, Jain RK.Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: Kinetics and potential biomarker value.Clin Cancer Res. 2010 Sep 15.
  • Chan JA, Zhu AX, Stuart K, Bhargava P, Earle CC, Clark JW, Casey C, Regan E, Kulke MH.Phase II study of pemetrexed in patients with advanced neuroendocrine tumors.Cancer Chemother Pharmacol. 2010 Oct;66(5):961-8.
  • Poultsides GA, Zhu AX, Choti MA, Pawlik TM.Intrahepatic cholangiocarcinoma.Surg Clin North Am. 2010 Aug;90(4):817-37. Review.
  • Hezel AF, Deshpande V, Zhu AX.Genetics of biliary tract cancers and emerging targeted therapies.J Clin Oncol. 2010 Jul 20;28(21):3531-40. Review.
  • Wu J, Henderson C, Feun L, Van Veldhuizen P, Gold P, Zheng H, Ryan T, Blaszkowsky LS, Chen H, Costa M, Rosenzweig B, Nierodzik M, Hochster H, Muggia F, Abbadessa G, Lewis J, Zhu AX.Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma.Invest New Drugs. 2010 Oct;28(5):670-6.
  • Eder JP, Shapiro GI, Appleman L, Zhu AX, Miles D, Keer HN, Cancilla B, Chu F, Hitchcock-Bryan S, Sherman L, McCallum SW, Heath EI, Boerner SA, Lorusso P.A Phase I Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Early Antitumor Activity of Foretinib.Clin Cancer Res. 2010 Jul 1;16(13):3507-16.
  • Burak KW, Thomas MB, Zhu AX.Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus conference.Hpb : The Official Journal Of The International Hepato Pancreato Biliary Association. 2010 Jun;12(5):321-2.
  • Rubbia-Brandt L, Lauwers GY, Wang H, Majno PE, Tanabe K, Zhu AX, Brezault C, Soubrane O, Abdalla EK, Vauthey JN, Mentha G, Terris B.Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis.Histopathology. 2010 Mar;56(4):430-9.
  • Zhu AX.Systemic treatment of hepatocellular carcinoma: dawn of a new era?.Ann Surg Oncol. 2010 May;17(5):1247-56. Review.
  • Zhu AX.Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma.Expert Opin Investig Drugs. 2010 May;19(5):663-72. Review.
  • Zhu AX, Hong TS, Hezel AF, Kooby DA.Current management of gallbladder carcinoma.Oncologist. 2010;15(2):168-81. Review.
  • Zhu AX, Meyerhardt JA, Blaszkowsky LS, Kambadakone AR, Muzikansky A, Zheng H, Clark JW, Abrams TA, Chan JA, Enzinger PC, Bhargava P, Kwak EL, Allen JN, Jain SR, Stuart K, Horgan K, Sheehan S, Fuchs CS, Ryan DP, Sahani DV.Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study.Lancet Oncol. 2010 Jan;11(1):48-54.
  • Lipworth AD, Robert C, Zhu AX.Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib.Oncology. 2009;77(5):257-71. Review.
  • Siegel AB, Zhu AX.Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link.Cancer. 2009 Dec 15;115(24):5651-61. Review.
  • Zhu AX, El-Khoueiry A, Llovet JM.Accomplishments in 2008 in the management of hepatobiliary cancers.Gastrointest Cancer Res. 2009 Sep;3(5 Supplement 2):S28-36.
  • Cleary JM, Tanabe KT, Lauwers GY, Zhu AX.Hepatic toxicities associated with the use of preoperative systemic therapy in patients with metastatic colorectal adenocarcinoma to the liver.Oncologist. 2009 Nov;14(11):1095-105. Review.
  • Zhu AX.Predicting the response to sorafenib in hepatocellular carcinoma: where is the evidence for phosphorylated extracellular signaling-regulated kinase (pERK)?.BMC Med. 2009;7:42.
  • Zhu AX, Duda DG, Sahani DV, Jain RK.Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies.Cancer J.;15(4):263-8. Review.
  • Vora SR, Zheng H, Stadler ZK, Fuchs CS, Zhu AX.Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma.Oncologist. 2009 Jul;14(7):717-25.
  • Zhu AX,Sahani DV,Duda DG,di Tomaso E,Ancukiewicz M,Catalano OA,Sindhwani V,Blaszkowsky LS,Yoon SS,Lahdenranta J,Bhargava P,Meyerhardt J,Clark JW,Kwak EL,Hezel AF,Miksad R,Abrams TA,Enzinger PC,Fuchs CS,Ryan DP,Jain RK.Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study.J Clin Oncol. 2009 Jun 20;27(18):3027-35.
  • Jain RK,Duda DG,Willett CG,Sahani DV,Zhu AX,Loeffler JS,Batchelor TT,Sorensen AG.Biomarkers of response and resistance to antiangiogenic therapy.Nat Rev Clin Oncol. 2009 Jun;6(6):327-338. Review.
  • Benson AB 3rd,Abrams TA,Ben-Josef E,Bloomston PM,Botha JF,Clary BM,Covey A,Curley SA,D'Angelica MI,Davila R,Ensminger WD,Gibbs JF,Laheru D,Malafa MP,Marrero J,Meranze SG,Mulvihill SJ,Park JO,Posey JA,Sachdev J,Salem R,Sigurdson ER,Sofocleous C,Vauthey JN,Venook AP,Goff LW,Yen Y,Zhu AX.NCCN Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers.J Natl Compr Canc Netw. 2009 Apr;7(4):350-91.
  • Finn RS,Zhu AX.Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab.Expert Rev Anticancer Ther. 2009 Apr;9(4):503-9. Review.
  • Goulart BH,Clark JW,Lauwers GY,Ryan DP,Grenon N,Muzikansky A,Zhu AX.Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis.J Hematol Oncol. 2009;2:13.
  • Zhu AX,Clark JW.Commentary: Sorafenib use in patients with advanced hepatocellular carcinoma and underlying Child-Pugh B cirrhosis: evidence and controversy.Oncologist. 2009 Jan;14(1):67-9.
  • Zhu AX,Ready N,Clark JW,Safran H,Amato A,Salem N,Pace S,He X,Zvereva N,Lynch TJ,Ryan DP,Supko JG.Phase I and pharmacokinetic study of gimatecan given orally once a week for 3 of 4 weeks in patients with advanced solid tumors.Clin Cancer Res. 2009 Jan 1;15(1):374-81.
  • Zhu AX,Raymond E.Early development of sunitinib in hepatocellular carcinoma.Expert Rev Anticancer Ther. 2009 Jan;9(1):143-50. Review.
  • Nathan H,Aloia TA,Vauthey JN,Abdalla EK,Zhu AX,Schulick RD,Choti MA,Pawlik TM.A proposed staging system for intrahepatic cholangiocarcinoma.Ann Surg Oncol. 2009 Jan;16(1):14-22.
  • Sainani NI,Catalano OA,Holalkere NS,Zhu AX,Hahn PF,Sahani DV.Cholangiocarcinoma: current and novel imaging techniques.Radiographics. 2008 Sep-Oct;28(5):1263-87. Review.
  • Asomaning K,Reid AE,Zhou W,Heist RS,Zhai R,Su L,Kwak EL,Blaszkowsky L,Zhu AX,Ryan DP,Christiani DC,Liu G.MDM2 promoter polymorphism and pancreatic cancer risk and prognosis.Clin Cancer Res. 2008 Jun 15;14(12):4010-5.
  • Llovet JM,Di Bisceglie AM,Bruix J,Kramer BS,Lencioni R,Zhu AX,Sherman M,Schwartz M,Lotze M,Talwalkar J,Gores GJ.Design and endpoints of clinical trials in hepatocellular carcinoma.Journal of the National Cancer Institute. 2008 May 21;100(10):698-711. Review.
  • Hezel AF, Zhu AX.Systemic therapy for biliary tract cancers.Oncologist. 2008 Apr;13(4):415-23. Review.
  • Zhu AX.Successful targeted therapies for hepatocellular carcinoma: are we really getting there?.Expert Rev Anticancer Ther. 2008 Apr;8(4):499-505.
  • Zhu AX, Abou-Alfa GK.Expanding the treatment options for hepatocellular carcinoma: combining transarterial chemoembolization with radiofrequency ablation.JAMA. 2008 Apr 9;299(14):1716-8.
  • Fuchs BC, Fujii T, Dorfman JD, Goodwin JM, Zhu AX, Lanuti M, Tanabe KK.Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells.Cancer Res. 2008 Apr 1;68(7):2391-9.
  • Zhu AX, Holalkere NS, Muzikansky A, Horgan K, Sahani DV.Early antiangiogenic activity of bevacizumab evaluated by computed tomography perfusion scan in patients with advanced hepatocellular carcinoma.Oncologist. 2008 Feb;13(2):120-5.
  • Meyerhardt JA, Zhu AX, Stuart K, Ryan DP, Blaszkowsky L, Lehman N, Earle CC, Kulke MH, Bhargava P, Fuchs CS.Phase-II Study of Gemcitabine and Cisplatin in Patients with Metastatic Biliary and Gallbladder Cancer.Dig Dis Sci. 2008 Feb;53(2):564-70.
  • Wheatley-Price P, Asomaning K, Reid A, Zhai R, Su L, Zhou W, Zhu A, Ryan DP, Christiani DC, Liu G.Myeloperoxidase and superoxide dismutase polymorphisms are associated with an increased risk of developing pancreatic adenocarcinoma.Cancer. 2008 Mar 1;112(5):1037-42.
  • Zhu AX.Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma.Cancer. 2008 Jan 15;112(2):250-9.
  • Ng K, Zhu AX.Targeting the epidermal growth factor receptor in metastatic colorectal cancer.Crit Rev Oncol Hematol. 2008 Jan;65(1):8-20. Review.
  • Kulke MH, Blaszkowsky LS, Ryan DP, Clark JW, Meyerhardt JA, Zhu AX, Enzinger PC, Kwak EL, Muzikansky A, Lawrence C, Fuchs CS.Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer.J Clin Oncol. 2007 Oct 20;25(30):4787-92.
  • Meyerhardt JA, Clark JW, Supko JG, Eder JP, Ogino S, Stewart CF, D'Amato F, Dancey J, Enzinger PC, Zhu AX, Ryan DP, Earle CC, Mayer RJ, Michelini A, Kinsella K, Fuchs CS.Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer.Cancer Chemother Pharmacol. 2007 Oct;60(5):661-70.
  • Meyerhardt J, Stuart K, Fuchs C, Zhu A, Earle C, Bhargava P, Blaszkowsky L, Enzinger P, Mayer R, Battu S, Lawrence C, Ryan D.Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastastic colorectal cancer.Ann Oncol. 2007 Jul;18(7):1185-9.
  • Zhu AX, Stuart K, Blaszkowsky LS, Muzikansky A, Reitberg DP, Clark JW, Enzinger PC, Bhargava P, Meyerhardt JA, Horgan K, Fuchs CS, Ryan DP.Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma.Cancer. 2007 Aug 1;110(3):581-9.
  • Sahani DV, Holalkere NS, Mueller PR, Zhu AX.Advanced Hepatocellular Carcinoma: CT Perfusion of Liver and Tumor Tissue--Initial Experience.Radiology. 2007 Jun;243(3):736-43.
  • Lockhart AC, Bukowski R, Rothenberg ML, Wang KK, Cooper W, Grover J, Appleman L, Mayer PR, Shapiro M, Zhu AX.Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors.Cancer Chemother Pharmacol. 2007 Jul;60(2):203-9.
  • Zhou X, Chen B, Hoopes PJ, Hasan T, Pogue BW.Tumor vascular area correlates with photosensitizer uptake: analysis of verteporfin microvascular delivery in the dunning rat prostate tumor.Photochem Photobiol. 2006 Sep-Oct;82(5):1348-57.
  • Kuruppu D, Brownell AL, Zhu A, Yu M, Wang X, Kulu Y, Fuchs BC, Kawasaki H, Tanabe KK.Positron emission tomography of herpes simplex virus 1 oncolysis.Cancer Res. 2007 Apr 1;67(7):3295-300.
  • Halyard MY, Jatoi A, Sloan JA, Bearden JD, Vora SA, Atherton PJ, Perez EA, Soori G, Zalduendo AC, Zhu A, Stella PJ, Loprinzi CL.Does Zinc Sulfate Prevent Therapy-Induced Taste Alterations in Head and Neck Cancer Patients? Results of Phase III Double-Blind, Placebo-Controlled Trial from the North Central Cancer Treatment Group (N01C4).Int J Radiat Oncol Biol Phys. 2007 Apr 1;67(5):1318-22.
  • Zhu AX, Clark JW, Ryan DP, Meyerhardt JA, Enzinger PC, Earle CC, Fuchs CS, Regan E, Anbe H, Houghton M, Zhang J, Urrea P, Kulke MH.Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer.Cancer Chemother Pharmacol. 2007 Feb;59(3):285-93.
  • Ryan DP, Appleman LJ, Lynch T, Supko JG, Fidias P, Clark JW, Fishman M, Zhu AX, Enzinger PC, Kashala O, Cusack J, Eder JP.Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors.Cancer. 2006 Nov 15;107(10):2482-9.
  • Wolpin BM, Clark JW, Meyerhardt JA, Earle CC, Ryan DP, Enzinger PC, Zhu AX, Blaszkowsky L, Battu S, Fuchs CS.Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer.Clin Colorectal Cancer. 2006 Sep;6(3):208-13.
  • Kulke MH, Bergsland EK, Ryan DP, Enzinger PC, Lynch TJ, Zhu AX, Meyerhardt JA, Heymach JV, Fogler WE, Sidor C, Michelini A, Kinsella K, Venook AP, Fuchs CS.Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors.J Clin Oncol. 2006 Aug 1;24(22):3555-61.
  • Kulke MH, Wu B, Ryan DP, Enzinger PC, Zhu AX, Clark JW, Earle CC, Michelini A, Fuchs CS.A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors.Dig Dis Sci. 2006 Jun;51(6):1033-8.
  • Meyerhardt JA, Heseltine D, Ogino S, Clark JW, Enzinger PC, Ryan DP, Earle CC, Zhu AX, Fuchs CS.Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase inhibitor-based chemotherapy in metastatic colorectal cancer.Clin Colorectal Cancer. 2006 May;6(1):59-65.
  • Meyerhardt JA, Zhu AX, Enzinger PC, Ryan DP, Clark JW, Kulke MH, Earle CC, Vincitore M, Michelini A, Sheehan S, Fuchs CS.Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer.J Clin Oncol. 2006 Apr 20;24(12):1892-7.
  • Zhu AX, Blaszkowsky LS, Ryan DP, Clark JW, Muzikansky A, Horgan K, Sheehan S, Hale KE, Enzinger PC, Bhargava P, Stuart K.Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma.J Clin Oncol. 2006 Apr 20;24(12):1898-903.
  • Eder JP, Ryan DP, Appleman L, Zhu AX, Puchalski T, He X, Sonnichsen DS, Cooper M, Wright J, Clark JW, Supko JG.Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumors.Cancer Chemother Pharmacol. 2006 Jul;58(1):107-116.
  • Willett CG, Boucher Y, Duda DG, di Tomaso E, Munn LL, Tong RT, Kozin SV, Petit L, Jain RK, Chung DC, Sahani DV, Kalva SP, Cohen KS, Scadden DT, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Shellito PC, Mino-Kenudson M, Lauwers GY.Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients.J Clin Oncol. 2005 Nov 1;23(31):8136-9.
  • Zhu AX, Fuchs CS, Clark JW, Muzikansky A, Taylor K, Sheehan S, Tam K, Yung E, Kulke MH, Ryan DP.A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma.Oncologist. 2005 Jun-Jul;10(6):392-8.
  • Tseng JF, Willett CG, Fernandez-del Castillo C, Ryan DP, Clark JW, Zhu AX, Rattner DW, Winkelmann JL, Warshaw AL.Patients undergoing treatment for pancreatic adenocarcinoma can mount an effective immune response to vaccinations.Pancreatology. 2005;5(1):67-74.
  • Willett CG, Del Castillo CF, Shih HA, Goldberg S, Biggs P, Clark JW, Lauwers G, Ryan DP, Zhu AX, Warshaw AL.Long-term results of intraoperative electron beam irradiation (IOERT) for patients with unresectable pancreatic cancer.Ann Surg. 2005 Feb;241(2):295-9.
  • Leung JY, Zhu AX, Gordon FD, Pratt DS, Mithoefer A, Garrigan K, Terella A, Hertl M, Cosimi AB, Chung RT.Liver transplantation outcomes for early-stage hepatocellular carcinoma: results of a multicenter study.Liver Transpl. 2004 Nov;10(11):1343-54.